All Stories

  1. Synthesis and Biological Evaluation of New Glycoconjugated LDH Inhibitors as Anticancer Agents
  2. First-of-its-kind STARD3 Inhibitor: In Silico Identification and Biological Evaluation as Anticancer Agent
  3. First Examples of H2S-Releasing Glycoconjugates: Stereoselective Synthesis and Anticancer Activities
  4. Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors
  5. Activators of Sirtuin-1 and their Involvement in Cardioprotection
  6. An Update on Patents Covering Agents That Interfere with the Cancer Glycolytic Cascade
  7. Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors
  8. A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017)
  9. Correction to Constituents of Polygala flavescens ssp. flavescens and Their Activity as Inhibitors of Human Lactate Dehydrogenase
  10. Constituents of Polygala flavescens ssp. flavescens and Their Activity as Inhibitors of Human Lactate Dehydrogenase
  11. Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer
  12. Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors
  13. Immune by Heart: Unexpected Observations Inspiring Perspective Therapeutic/Preventive Strategies against Cancer
  14. Risks and benefits related to alimentary exposure to xenoestrogens
  15. Anticancer agents interacting with membrane glucose transporters
  16. Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase
  17. Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model
  18. Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroyxindole class LDH inhibitors as anticancer agents
  19. CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1 H )-one-3-carboxamides
  20. Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential
  21. An update on therapeutic opportunities offered by cancer glycolytic metabolism
  22. Identification and characterization of a new reversible MAGL inhibitor
  23. Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways
  24. Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells
  25. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia
  26. Dual Targeting of the Warburg Effect with a Glucose-Conjugated Lactate Dehydrogenase Inhibitor
  27. Identification of New Fyn Kinase Inhibitors Using a FLAP-Based Approach
  28. Small-molecule inhibitors of human LDH5
  29. Estrogen receptor ligands: a patent review update
  30. Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors
  31. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds
  32. Anticancer Agents That Counteract Tumor Glycolysis
  33. Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5
  34. N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation
  35. Carbazole-containing arylcarboxamides as BACE1 inhibitors
  36. Curaxins: A New Family of Non-genotoxic Multitargeted Anticancer Agents
  37. Antiproliferative Activity and Cell Cycle Analysis of 2-(3,5-Dihydroxyphenyl)-6-Hydroxybenzothiazole on MCF-7 Breast and HCT-15 Colon Cancer Cell Lines
  38. Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes
  39. Discovery of N -Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells
  40. Triazole-substituted N-hydroxyindol-2-carboxylates as inhibitors of isoform 5 of human lactate dehydrogenase (hLDH5)
  41. BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides
  42. Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties
  43. Biphenyl-Derivatives Possessing Tertiary Amino Groups as β-Secretase (BACE1) Inhibitors
  44. Study of Apoptosis Induction and Deoxycytidine Kinase/Cytidine Deaminase Modulation in the Synergistic Interaction of a Novel Ceramide Analog and Gemcitabine in Pancreatic Cancer Cells
  45. Inhibitors of Lactate Dehydrogenase Isoforms and their Therapeutic Potentials
  46. Estrogen receptor β ligands: Recent advances and biomedical applications
  47. Bioreductively Activated Lysyl Oxidase Inhibitors against Hypoxic Tumours
  48. QSAR models for predicting enzymatic hydrolysis of new chemical entities in ‘soft-drug’ design
  49. Structural Evolutions of Salicylaldoximes as Selective Agonists for Estrogen Receptor β
  50. Spirocyclic Benzopyran-Based Derivatives as New Anti-ischemic Activators of Mitochondrial ATP-Sensitive Potassium Channel
  51. α-Naphthylaminopropan-2-ol Derivatives as BACE1 Inhibitors
  52. Monoaryl-Substituted Salicylaldoximes as Ligands for Estrogen Receptor β
  53. Evaluation of the NO-releasing properties of NO-donor linkers
  54. Synthesis and Affinity Evaluation for AT1 Receptor of Phenylsalicylaldoxime-Derivatives Structurally Related to Sartans
  55. Metabolically labile cannabinoid esters: A ‘soft drug’ approach for the development of cannabinoid-based therapeutic drugs
  56. New Benzopyran-Based Openers of the Mitochondrial ATP-Sensitive Potassium Channel with Potent Anti-Ischemic Properties
  57. Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes
  58. New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite:  Design, Synthesis, and Biopharmacological Properties
  59. N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation
  60. Synthesis of Stable Analogues of Geranylgeranyl Diphosphate Possessing a (Z,E,E)-Geranylgeranyl Side Chain, Docking Analysis, and Biological Assays for Prenyl Protein Transferase Inhibition
  61. Synthesis of a Resveratrol Analogue with High Ceramide-Mediated Proapoptotic Activity on Human Breast Cancer Cells
  62. Variously Substituted (Phosphonoacetamido)Oxy Analogues of Geranylgeranyl Diphosphate (GGdP) as GGdP-transferase (GGTase) Inhibitors and Antiproliferative Agents
  63. Stable propylphosphonic acid analogues of geranylgeranyl diphosphate possessing inhibitory activity on geranylgeranyl protein transferase
  64. Phosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitors
  65. NO-Sartans:  A New Class of Pharmacodynamic Hybrids as Cardiovascular Drugs
  66. Diaryl-substituted salicyl- and anthranyl-ketoximes as potential estrogen receptor ligands
  67. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2)
  68. Synthesis and COX-2 inhibitory properties of N-phenyl- and N-benzyl-substituted amides of 2-(4-methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic acid and of their pyrazole, thiophene and isoxazole analogs
  69. Synthesis of aniline-type analogues of farnesyl diphosphate and their biological assays for prenyl protein transferase inhibitory activity
  70. Stable analogues of geranylgeranyl diphosphate possessing improved geranylgeranyl versus farnesyl protein transferase inhibitory selectivity
  71. Novel Estrogen Receptor Ligands Based on an Anthranylaldoxime Structure:  Role of the Phenol-Type Pseudocycle in the Binding Process
  72. Synthesis, binding affinity, and transcriptional activity of hydroxy- and methoxy-Substituted 3,4-Diarylsalicylaldoximes on estrogen receptors α and β
  73. Ceramide analogues in apoptosis: a new strategy for anticancer drug development
  74. Synthesis of heteroaromatic analogues of (2-aryl-1-cyclopentenyl-1-alkylidene)-(arylmethyloxy)amine COX-2 inhibitors: effects on the inhibitory activity of the replacement of the cyclopentene central core with pyrazole, thiophene or isoxazole ring
  75. New N - n -Propyl-Substituted 3-Aryl- and 3-Cyclohexylpiperidines as Partial Agonists at the D 4 Dopamine Receptor
  76. Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity
  77. 4-[6-(Dansylamino)hexylamino]-7-methyl-2-phenyl-1,8-naphthyridine as a new potential fluorescent probe for studying A1-adenosine receptor
  78. Aryl-substituted methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: effects of some structural modifications on their biological properties
  79. 7-Nitrobenzofurazan (NBD) derivatives of 5′-N-ethylcarboxamidoadenosine (NECA) as new fluorescent probes for human A3 adenosine receptors
  80. Design, Synthesis, and Characterization of the Antitumor Activity of Novel Ceramide Analogues †
  81. Salicylaldoxime Moiety as a Phenolic “A-Ring” Substitute in Estrogen Receptor Ligands
  82. Purification, Enzymatic Characterization, and Inhibition of the Z-Farnesyl Diphosphate Synthase from Mycobacterium tuberculosis
  83. Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand
  84. Synthesis and antiviral properties of novel analogues of monophosphate and diphosphate bioactive forms of acyclovir
  85. Synthesis and antiviral properties of 9-[(2-methyleneaminoxyethoxy)methyl]guanine derivatives as novel Acyclovir analogues
  86. Crystallographic evidence for the electronic distribution in (2,4-cyclopentadien-1-ylidenehydrazono)triphenylphosphorane
  87. Three-Component Synthesis of Substituted η 5 -Cyclopentadienyltricarbonylrhenium Complexes:  Scope, Limitations, and Mechanistic Interpretations
  88. A Polymer-Supported Phosphazine as a Stable and Practical Reagent in the Three-Component Synthesis of Substituted (Cyclopentadienyl)tricarbonylrhenium Complexes
  89. Boronic Acids in the Three-Component Synthesis of Carbon-Substituted Cyclopentadienyl Tricarbonyl Rhenium Complexes
  90. A Convenient Three-Component Synthesis of Substituted Cyclopentadienyl Tricarbonyl Rhenium Complexes
  91. Heterogeneous asymmetric epoxidation of unfunctionalized olefins catalyzed by polymer-bound (salen)manganese complexes
  92. Polymer-bound chiral (salen)Mn(III) complex as heterogeneous catalyst in rapid and clean enantioselective epoxidation of unfunctionalised olefins
  93. Efficient application of lipase-catalyzed transesterification to the resolution of γ-hydroxy ketones
  94. Asymmetric Synthesis of the Dihydroisocoumarin Moiety of AI-77-B via Copper-Mediated Cross-Coupling and Sharpless Asymmetric Dihydroxylation
  95. Anomalous Face-Selectivity in Sharpless Asymmetric Dihydroxylation of o -Allylbenzamides
  96. Aromatic substituent effect on the stereoselectivity of the gas-phase acid-induced ring opening in 9,10-oxides derived from trans-1,2,3,4,4a,10a-hexahydrophenanthrene